The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Open accessAbstract
Several potential disease‐modifying drugs for Alzheimer's disease (AD) have failed to show any effect on disease progression in clinical trials, conceivably because the AD subjects are already too advanced to derive clinical benefit from treatment and because diagnosis based on clinical criteria alone introduces a high misdiagnosis rate. Thus, well‐validated biomarkers for early detection and accurate diagnosis are crucial. Low cerebrospinal fluid (CSF) concentrations of the amyloid‐β (Aβ 1‐42) peptide, in combination with high total tau and phosphorylated tau, are sensitive and specific biomarkers highly predictive of progression to AD dementia in patients with mild cognitive impairment. However, interlaboratory variations in the results seen with currently available immunoassays are of concern. Recent worldwide standardization efforts and quality control programs include standard operating procedures for both preanalytical (e.g., lumbar puncture and sample handling) and analytical (e.g., preparation of calibration curve) procedures. Efforts are also ongoing to develop highly reproducible assays on fully automated instruments. These global standardization and harmonization measures will provide the basis for the generalized international application of CSF biomarkers for both clinical trials and routine clinical diagnosis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“This is supported in some biomarker studies in sporadic AD that showed that lowering of Ab42 in CSF is a very early change [49,50], but studies on familial AD suggest that reductions in CSF Ab42 and elevations in tau compared with normal occur around 10 to 15 years before the expected onset of symptoms [51,52].”
ResultSelf-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · Radiology · doi:10.1148/radiol.2261021292 · Cited by 3,215
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“In addition, reports from large clinical trials of drug candidates with disease-modifying potential show that 10% to 35% of clinically diagnosed AD cases with mild-to-moderate dementia have negative amyloid positron emission tomography (PET) scans [18].”
BackgroundSelf-citationRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“It is now the opinion among experts that combined Ab42, T-tau, and P-tau provide distinctive and reliable biomarkers for AD [21,28,78–80].”
BackgroundSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Alzheimer’s Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2007) · Advances in Behavioral Biology · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,468
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Self-citationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“The accuracy of current clinical AD diagnostic methods to predict pathologic diagnoses (in the absence of biomarker information) is generally low; sensitivities have been reported to range from 71% to 88% and specificities from 44% to 71%, depending on the specific histopathologic diagnostic criteria used [17].”
Background2011 Alzheimer's disease facts and figures
Alzheimer's Association (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.004 · Cited by 908
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 3×
“The evidence for the benefit of CSF biomarkers in AD research is highly compelling as many studies have shown the utility of the AD signature (low Ab42 together with high T-tau and P-tau) for AD diagnosis and have demonstrated its use as a predictor of disease progression [56,59,60,62,103,111,112].”
BackgroundSelf-citationTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., Ringheim, A., Långström, B., & Nordberg, A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 728
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660
Self-citationBiomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Self-citationde Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 612
Self-citationMorris, J. C., Storandt, M., McKeel, D. W., Rubin, E. H., Price, J. L., Grant, E. A., & Berg, L. (1996) · Neurology · doi:10.1212/wnl.46.3.707 · Cited by 603
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Self-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“Some studies suggest that CSF Ab and tau may predict future cognitive decline in cognitively normal elderly individuals [66], whereas other studies report that the reduction in CSF Ab42 may be more predictive of future cognitive decline than high CSF tau [67].”
BackgroundSelf-citationHippocampal formation glucose metabolism and volume losses in MCI and AD
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, W. H., Kandil, E., Boppana, M., Daisley, K., et al. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00230-5 · Cited by 548
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Cerebrospinal fluid protein biomarkers for Alzheimer’s disease
Blennow, K. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.213 · Cited by 477
Self-citationAmnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study
Sarazin, M., Berr, C., De Rotrou, J., Fabrigoule, C., Pasquier, F., Legrain, S., Michel, B., Puel, M., Volteau, M., Touchon, J., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000279336.36610.f7 · Cited by 468
Self-citationRelationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 2×
“In addition, decreased CSF concentrations of Ab42 have been found to correlate with high retention of Pittsburgh Compound B using PET [30,32–36].”
BackgroundTransient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Hesse, C., Rosengren, L., Andreasen, N., Davidsson, P., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01697-9 · Cited by 450
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 437
Self-citationThe Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Mattsson, N., Andreasson, U., Persson, S., Arai, H., Batish, S. D., Bernardini, S., Bocchio‐Chiavetto, L., Blankenstein, M. A., Carrillo, M. C., Chalbot, S., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2243 · Cited by 413
Self-citationComparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 396
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation.
de Leon, M. J., Golomb, J. B., GEORGE, A. E., Convit, A. J., Tarshish, C. Y., McRae, T., Santi, S. D., Smith, G. S., Ferris, S. H., & Noz, M. E. (1993) · PubMed · Cited by 370
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · cited 1×
“The risk of serious adverse effects from investigative treatments should not be underestimated [110], and although rigorous toxicity studies are performed on all new drugs, rare side effects are often detected only after widespread use [109].”
BackgroundFagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Self-citationdel Campo, M., Mollenhauer, B., Bertolotto, A., Engelborghs, S., Hampel, H., Simonsen, A. H., Kapaki, E., Kruse, N., Le Bastard, N., Lehmann, S., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.46 · Cited by 343 · cited 1×
“It is clear that measures need to be undertaken to optimize biomarker analysis, and to facilitate this, standard operating procedures (SOPs) concerning standardization of sample processing, laboratory techniques, and assay execution have been proposed to reduce the variability and increase the diagnostic utility of AD…”
BackgroundSelf-citationInitial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
Öst, M., Nylén, K., Csajbok, L., Öhrfelt, A. O., Tullberg, M., Wikkelsö, C., Nellgård, P., Rosengren, L., Blennow, K., & Nellgård, B. (2006) · Neurology · doi:10.1212/01.wnl.0000242732.06714.0f · Cited by 321
Self-citationHULETTE, C. M., WELSH-BOHMER, K. A., MURRAY, M. G., SAUNDERS, A. M., MASH, D. C., & MCINTYRE, L. M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199812000-00009 · Cited by 311
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Walhovd, K. B., Fjell, A. M., Brewer, J., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jennings, R. G., Karow, D., Dale, A. M., & Initiative, T. A. D. N. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1809 · Cited by 279
CSF Total tau, Aβ42 and Phosphorylated tau Protein as Biomarkers for Alzheimer's Disease
Blennow, K., Vanmechelen, E., & Hampel, H. (2001) · Molecular Neurobiology · doi:10.1385/mn:24:1-3:087 · Cited by 267
Self-citationLongitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment
de Leon, M. J., DeSanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., Rusinek, H., Li, J., Tsui, W., Saint Louis, L. A., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.003 · Cited by 253
Self-citationAndreasen, N., Minthon, L., Vanmechelen, E., Vanderstichele, H., Davidsson, P., Winblad, B., & Blennow, K. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00617-5 · Cited by 239
Self-citationRiemenschneider, M., Wagenpfeil, S., Vanderstichele, H., Otto, M., Wiltfang, J., Kretzschmar, H., Vanmechelen, E., Förstl, H., & Kurz, A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001220 · Cited by 238 · cited 3×
“In addition, CSF T-tau shows a verymarked increase in CJD, thus having diagnostic value in rapidly progressing dementias.”
BackgroundCSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Snider, B. J., Fagan, A. M., Roe, C., Shah, A. R., Grant, E. A., Xiong, C., Morris, J. C., & Holtzman, D. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.55 · Cited by 228
Self-citationCerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214
Self-citationFluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
Self-citationPractical Guidelines for the Recognition and Diagnosis of Dementia
Galvin, J. E., & Sadowsky, C. H. (2012) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2012.03.100181 · Cited by 201
Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease
De LEON, M. J., MOSCONI, L., BLENNOW, K., DeSANTI, S., ZINKOWSKI, R., MEHTA, P. D., PRATICO, D., TSUI, W., LOUIS, L. A. S., SOBANSKA, L., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.012 · Cited by 200
Self-citationSkoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Self-citationCarpenter, B. D., Xiong, C., Porensky, E. K., Lee, M. M., Brown, P. J., Coats, M., Johnson, D., & Morris, J. C. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01600.x · Cited by 194
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.064 · Cited by 193
Self-citationFagan, A. M., Shaw, L. M., Xiong, C., Vanderstichele, H., Mintun, M. A., Trojanowski, J. Q., Coart, E., Morris, J. C., & Holtzman, D. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.105 · Cited by 189
Self-citationPrediction and longitudinal study of CSF biomarkers in mild cognitive impairment
Brys, M., Pirraglia, E., Rich, K., Rolstad, S., Mosconi, L., Switalski, R., Glodzik-Sobanska, L., De Santi, S., Zinkowski, R., Mehta, P., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.010 · Cited by 185
Self-citationBlom, E. S., Giedraitis, V., Zetterberg, H., Fukumoto, H., Blennow, K., Hyman, B. T., Irizarry, M. C., Wahlund, L., Lannfelt, L., & Ingelsson, M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000216841 · Cited by 183
Self-citationBiomarker validation of a cued recall memory deficit in prodromal Alzheimer disease
Wagner, M., Wolf, S., Reischies, F. M., Daerr, M., Wolfsgruber, S., Jessen, F., Popp, J., Maier, W., Hüll, M., Frölich, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f447 · Cited by 174
Self-citationDiniz, B. S. O., Pinto, J. A., & Forlenza, O. V. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701535502 · Cited by 170
Verwey, N. A., van der Flier, W. M., Blennow, K., Clark, C., Sokolow, S., De Deyn, P. P., Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., et al. (2009) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2009.008232 · Cited by 169
Self-citationStomrud, E., Hansson, O., Blennow, K., Minthon, L., & Londos, E. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105017 · Cited by 167
Self-citationLewczuk, P., Kamrowski-Kruck, H., Peters, O., Heuser, I., Jessen, F., Popp, J., Bürger, K., Hampel, H., Frölich, L., Wolf, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.84 · Cited by 161
Self-citationAndreasen, N., Vanmechelen, E., Vanderstichele, H., Davidsson, P., & Blennow, K. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.9.x · Cited by 160
Self-citationBiological markers of amyloid β-related mechanisms in Alzheimer's disease
Hampel, H., Shen, Y., Walsh, D. M., Aisen, P., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 160
Self-citationRelationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
Tolboom, N., van der Flier, W. M., Yaqub, M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064360 · Cited by 160
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
Sämgård, K., Zetterberg, H., Blennow, K., Hansson, O., Minthon, L., & Londos, E. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2353 · Cited by 158
Self-citationBraak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156
Self-citationHampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 152
Self-citationChoi, S., Schneider, J. A., Bennett, D. A., Beach, T. G., Bedell, B. J., Zehntner, S. P., Krautkramer, M. J., Kung, H. F., Skovronsky, D., Hefti, F. F., et al. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31821300bc · Cited by 142
Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years
Zetterberg, H., Pedersen, M., Lind, K., Svensson, M., Rolstad, S., Eckerström, C., Syversen, S., Mattsson, U.-B., Ysander, C., Mattsson, N., et al. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12307 · Cited by 134
Self-citationLow Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients
Zetterberg, H., Tullhög, K., Hansson, O., Minthon, L., Londos, E., & Blennow, K. (2010) · European Neurology · doi:10.1159/000311703 · Cited by 116
Self-citationLewczuk, P., Kornhuber, J., Vanmechelen, E., Peters, O., Heuser, I., Maier, W., Jessen, F., Bürger, K., Hampel, H. J., Frölich, L., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.024 · Cited by 115
Self-citationAluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 108
International quality control survey of neurochemical dementia diagnostics
Lewczuk, P., Beck, G., Ganslandt, O., Esselmann, H., Deisenhammer, F., Regeniter, A., Petereit, H.-F., Tumani, H., Gerritzen, A., Oschmann, P., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.009 · Cited by 107
Self-citationRelationship of dementia screening tests with biomarkers of Alzheimer's disease
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A., & Morris, J. C. (2010) · Brain · doi:10.1093/brain/awq204 · Cited by 107
Self-citationCerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 102
Self-citationβ‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Wiltfang, J., Esselmann, H., Av, S., Bibl, M., Cepek, L., Steinacker, P., Mollenhauer, B., Büerger, K., Hampel, H. J., Paul, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10661 · Cited by 91
Self-citationTo Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease
Mattsson, N., Brax, D., & Zetterberg, H. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/841941 · Cited by 90
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
Vos, S. J. B., van Rossum, I., Burns, L. C., Knol, D. L., Scheltens, P., Soininen, H. S., Wahlund, L., Hampel, H. J., Tsolaki, M., Minthon, L., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.017 · Cited by 90
Self-citationNeurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers
Lewczuk, P., Zimmermann, R., Wiltfang, J., & Kornhuber, J. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0277-y · Cited by 89
Self-citationSanti, S. D., Pirraglia, E., Barr, W., Babb, J. S., Williams, S., Rogers, K., Glodzik, L., Bryś, M., Mosconi, L., Reisberg, ., et al. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.469 · Cited by 87
Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment
Mattsson, N., Portelius, E., Rolstad, S., Gustavsson, M. K., Andréasson, U., Stridsberg, M., Wallin, A., Blennow, K., & Zetterberg, H. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120019 · Cited by 79
Self-citationMosconi, L., Tsui, W.-H., Pupi, A., Santi, S. D., Drzezga, A. E., Minoshima, S., & de Leon, M. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.040675 · Cited by 77
Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease
Quinn, J. F., Montine, K. S., Moore, M. M., Morrow, J. D., Kaye, J. A., & Montine, T. J. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6110 · Cited by 75
Sjögren, M. J. C., Gisslén, M., Vanmechelen, E., & Blennow, K. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02285-6 · Cited by 73
Self-citationDiagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β42 and Tau Proteins
Reijn, T. S., Rikkert, M. G. M. O., van Geel, W. J. A., de Jong, D., & Verbeek, M. M. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081679 · Cited by 73
Teunissen, C. E., Verwey, N. A., Kester, M. I., van Uffelen, K. W. J., & Blankenstein, M. A. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/635053 · Cited by 72
Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment
de Leon, M. J., Segal, S., Tarshish, C. Y., DeSanti, S., Zinkowski, R. P., Mehta, P. D., Convit, A. J., Caraos, C., Rusinek, H., Tsui, W., et al. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01038-8 · Cited by 70
Can primary care record review facilitate earlier diagnosis of dementia?
Bamford, C., Eccles, M., Steen, N., & Robinson, L. A. (2007) · Family Practice · doi:10.1093/fampra/cml068 · Cited by 69
Bryś, M., Glodzik, L., Mosconi, L., Switalski, R., Santi, S. D., Pirraglia, E., Rich, K. E., Kim, B. C., Mehta, P. D., Zinkowski, R., et al. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0968 · Cited by 68
Self-citationSafety of Lumbar Puncture Procedures in Patients with Alzheimers Disease
Peskind, E., Nordberg, A., Darreh-Shori, T., & Soininen, H. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486509 · Cited by 66
Trojanowski, J. Q., & Hampel, H. J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.07.004 · Cited by 59
Self-citationPhosphorylated tau 231, memory decline and medial temporal atrophy in normal elders
Glodzik, L., Santi, S. D., Tsui, W. H., Mosconi, L., Zinkowski, R. P., Pirraglia, E., Wang, H. Y., Li, Y., Rich, K. E., Zetterberg, H., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.12.026 · Cited by 56
Self-citationImplications of the Facing Dementia Survey for health care professionals across Europe
Wilkinson, D., Sganga, A., Stave, C., & O'Connell, B. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2005.00484.x · Cited by 49
Ringman, J. M., Coppola, G., Elashoff, D. A., Rodríguez‐Agudelo, Y., Medina, L. D., Gylys, K. H., Cummings, J. L., & Cole, G. M. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335729 · Cited by 47
Wallin, A., Hansson, O., Blennow, K., Londos, E., & Minthon, L. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2195 · Cited by 44
Self-citationPerspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease
Teipel, S. J., Sabri, O., Grothe, M. J., Barthel, H., Prvulovic, D., Büerger, K., Bokde, A. L. W., Ewers, M., Hoffmann, W. U., & Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129030 · Cited by 28
Self-citationPrice (1999) · doi:10.1002/1531-8249(199903)45:3
Cited by
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationJohnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“As such, CSF biomarkers are widely accepted within the AD community to support a diagnosis (80).”
Multimodal deep learning models for early detection of Alzheimer’s disease stage
Venugopalan, J., Tong, L., Hassanzadeh, H. R., & Wang, M. D. (2021) · Scientific Reports · doi:10.1038/s41598-020-74399-w · Cited by 732
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Self-citation
Metadata
- Authors
- Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-05-02
- Volume
- 11
- Issue
- 1
- Pages
- 58-69
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1980314710
- Cited by
- 455
- References
- 115
- FWCI
- 28.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.